Xcout Intel
MCAL Therapeutics Inc.
MCAL Therapeutics Inc. is a biotechnology company developing synthetic, rabbit-inspired lipid eye drops and extended-release drug delivery platforms. Its lead candidate, MCAL-201, is designed to treat evaporative dry eye disease by restoring the tear film's protective lipid barrier.
Subscribe to see MCAL Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MCAL Therapeutics Inc. at a glance
MCAL Therapeutics Inc. is a biotechnology company headquartered in United States. It has raised at least $6.3M across the 2 funding rounds on record. Its most recent funding round raised $5.9M in March 2024. Xcout tracks 7 named people at MCAL Therapeutics Inc., including Mary Newman (Chief Regulatory Officer).
MCAL Therapeutics Inc. leadership
- Mary NewmanChief Regulatory Officer
- Tom MatherChief Medical Officer
- Chuck O’NeillCEO, Co-Founder, Chair of the Board of Directors
- Chris MurphyCo-Founder and Expert in Corneal and Ocular Surface Diseases, Distinguished Professor of Comparative Ophthalmology Emeritus, University of California, Davis
- Tom GadekEmeritus Board Member and Co-Founder
- G. Eric DavisExecutive Vice President, Chief Legal Officer at BioMarin Pharmaceutical Inc.
1 more named person on record for MCAL Therapeutics Inc., with roles, board committees and tenure — see the full roster →
MCAL Therapeutics Inc. funding rounds
At least $6.3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5.9M | — | |
| — | $450,000 | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
MCAL Therapeutics Inc. competitors
A few of MCAL Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Opal Biosciences (operating as Opal Therapeutics) is a biotechnology company that develops patient-derived uterine organoids to model human reproductive biology. The company provides research and drug discovery platforms to help researchers study conditions like endometriosis and uterine fibroids, serving the biotechnology and pharmaceutical research sectors.
Relation Therapeutics Inc. is an active for-profit biotechnology company founded in 2019 that focuses on therapeutic development.
Maxwell Biosciences, Inc. is a biotechnology company based in Austin, Texas. It develops biomimetic, peptide-inspired anti-infective drugs designed to act as a synthetic immune system.
Tasca Therapeutics is a biotechnology research company based in Cambridge, Massachusetts, leveraging a unique platform to exploit lipid-binding pockets on proteins.
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
Scala Biodesign develops computational protein design technologies to optimize enzymes, antibodies, therapeutic proteins, and antigens for industries such as pharmaceuticals and chemicals.
Get MCAL Therapeutics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MCAL Therapeutics Inc. in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access